Nuclidium, PharmaLogic Partner for Sustainable Development of Copper-based Theranostics

Nuclidium and PharmaLogic Holdings entered into a collaboration agreement for the production and clinical supply of copper (Cu) in the U.S. to accelerate the development of Nuclidium’s theranostic pipeline. By combining copper radiometals with highly specific cancer-targeting molecules, Nuclidium’s theranostic approach aims to offer innovative diagnostic and therapeutic treatments for patients suffering from a range of solid tumors.

The partnership with PharmaLogic will provide Nuclidium with a sustainable supply of Cu in the U.S. both for its planned clinical trials as well as future commercialized products. Nuclidium has developed a proprietary production process for high-quality Cu, a novel diagnostic radioisotope that offers unique properties for safe, economical, and highly efficient diagnostics to improve cancer-staging and subsequent treatment decisions.

Under the terms of the agreement, Nuclidium will provide PharmaLogic with the scientific know-how, proprietary technology, and raw material to enable PharmaLogic to safely and accurately produce high-quality Cu-radionuclides and radiopharmaceuticals in their manufacturing facilities throughout the U.S. The first product batch is planned to be manufactured in 2023 at PharmaLogic’s location in Los Angeles, California. Nuclidium will retain all rights to its proprietary platforms and technologies. Financial details of the collaboration were not disclosed.

“PharmaLogic is a well-established and highly experienced CDMO with a robust manufacturing network to supply diagnostic and therapeutic radiopharmaceuticals across North America,” said Leila Jaafar, CEO and co-founder of Nuclidium.” Their commitment to work with us emphasizes the opportunity represented by our innovative theranostic approach. With this agreement, we are further ensuring the sustainable supply of copper-based isotopes to advance our programs towards the clinic, specifically two of our pipeline candidates which are targeted to reach the clinic this year.”

“Targeted radiotheranostics offer a novel, personalized solution for cancer patients with the potential to become an integral part of cancer diagnosis and treatment,” said Steve Chilinski, CEO of PharmaLogic. “Nuclidium’s copper-based platform has the ability to bring us closer to this vision, and I look forward to working with this highly skilled team to advance radiopharmaceutical products jointly and serve cancer patients in North America by reliably providing them with clinically relevant medical options.”